Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - melphalan, quantity: 50 mg - injection, powder for - excipient ingredients: povidone; hydrochloric acid - for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciprofloxacin hydrochloride 0.35% equivalent to 0.3% ciprofloxacin - eye drops, solution - 0.3 % - active: ciprofloxacin hydrochloride 0.35% equivalent to 0.3% ciprofloxacin excipient: acetic acid benzalkonium chloride disodium edetate dihydrate mannitol purified water sodium acetate trihydrate - treatment of corneal ulcers, conjunctivitis and blepharitis caused by susceptible strains of bacteria in adults and children 12 months of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - ear drops, solution - excipient ingredients: mannitol; purified water; benzalkonium chloride; sodium hydroxide; disodium edetate; sodium acetate; hydrochloric acid; glacial acetic acid - treatment of chronic suppurative otitis media caused by organisms susceptible to ciprofloxacin in adults and children one month of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; mannitol; sodium hydroxide; purified water; hydrochloric acid; disodium edetate; glacial acetic acid; sodium acetate - treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjunctivitis caused by organisms susceptible to ciprofloxacin in adults and children 12 months of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: sodium hydroxide; benzalkonium chloride; sodium acetate; glacial acetic acid; purified water; disodium edetate; hydrochloric acid; mannitol - treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjuctivitis caused by organisms susceptible to ciprofloxacin. indications as at 25 july 1996: treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjunctivitis caused by organisms susceptible to ciprofloxacin in adults and children 12 months of age or older.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 50mg - solution for injection - 50 mg - active: melphalan 50mg excipient: hydrochloric acid povidone ethanol propylene glycol sodium citrate dihydrate

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 1 mg - warfarin sodium 1 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 3 mg - warfarin sodium 3 mg